Analytical and Chemical Enhancements to Improve Efficacy and Accuracy of Therapeutic Oligonucleotides
See how top pharma players are addressing impure, unstable, and off-target oligos
Boosting the Efficacy of Safe, Scalable, & Precise Vaccines
Innovations in mRNA Technology, RNA Therapeutics, and Cancer Immunotherapy for 2024
.png)
Tumbler: A Highly Customizable Antibody Optimization Suite
On-demand presentation, presented by Michali Izhaky, Bioinformatics Scientist at Charles River
Leading Innovations in Fab, ScFv, & VHH Production and Engineering
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy
On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological
Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Immuno-Oncology
Finding New Immunotherapy Targets for Solid Brain Tumour CAR Ts with RNAseq in Cancer-Specific Exons
The project has found over 150 target candidates for solid brain tumour therapies.
"World's First" IND Approval for Epstein-Barr mRNA Cancer Vaccine
Epstein-Barr virus has been highly linked to over ten forms of cancer. This wide range of malignant implications means an expanded variety of target indications for the vaccine.
Manufacturing & Bioprocessing
Implementing Process Analytical Technology into Cell and Gene Therapy Manufacturing
A recent study shows that a novel refractometry-based PAT system monitors metabolic activity during CGT production, revealing insights into optimising bioprocesses.
Immuno-Oncology
Patients Enter Clinic for Phase III mRNA Immunotherapy for High Risk Melanoma
The trial will test the world's first mRNA-based personalised immunotherapy for melanoma.
Stem Cell Therapy
In Conversation with Stephen Sullivan, COO of iPSirius
Cell & Gene 2024 Conference Producer Anya Chuykov met with Stephen Sullivan, COO of iPSirius, to discuss the advancements being made by iPSirius, and their unique proprietary technology working to treat aggressive forms of cancer.
Immunotherapy (Non-Oncology)
First Patient Dosed with NK Cell Therapy for the Treatment of an Autoimmune Disease, Lupus Nephritis
The NK cell therapy is being trialled in combination with monoclonal antibody therapy and hopes to induce B-cell depletion.
Peptide Chemistry
Sustainable Pharma: Celebrating Progress and Confronting Challenges on Earth Day
Earth Day marks a moment to reflect on the planet's health and our collective efforts to nurture it. To celebrate Earth Day, this article will examine the strides the pharmaceutical and biotechnology industry has made towards fostering sustainable and green practices alongside the challenges.
Antibody & Protein Engineering
Rapid Analytical Approach for Biologics Characterization Using Mass Photometry
On-demand webinar featuring Dr Racha Majed, Technical Sales Specialist, Refeyn
NextGen Therapeutics
Merus's Preclinical Bispecific Zeno Demonstrates Efficacy in Cancer Models
Zeno interrupts the dimerization of HER2 and HER3 and prevents NRG1/HER3 tumour signalling.
Drug Discovery & Development
Positive Results from iNKT Cell Therapy Clinical Trial for COVID-19 ARDS
The small exploratory trial shows signs that iNKT cells can improve the survival rate of respiratory distress from COVID-19.
Cell Line Development
UNIVERCell: Engineering Red Blood Cells for Targeted Therapy
Scarlet Therapeutics uses genetic manipulation of red blood cells to carry a higher load of therapeutic proteins to help treat rare metabolic diseases.
Cell Line Development
Enhancing Gene Editing Efficiency: Multi-Tailed mRNA Integration in CRISPR-Cas9 Systems
A study conducted by the Broad Institute and the Massachusetts Institute of Technology (MIT) demonstrated that when multi-tailed mRNAs were integrated into a CRISPR-Cas9 system they proved to be more efficient gene editors than unmodified mRNA.